129 related articles for article (PubMed ID: 8388065)
1. [The measurement of superoxide generation and eosinophil peroxidase (EPO) from eosinophils].
Okada C; Soda R; Takahashi K
Nihon Rinsho; 1993 Mar; 51(3):730-5. PubMed ID: 8388065
[TBL] [Abstract][Full Text] [Related]
2. The induction of eosinophil peroxidase release: improved methods of measurement and stimulation.
Adamko DJ; Wu Y; Gleich GJ; Lacy P; Moqbel R
J Immunol Methods; 2004 Aug; 291(1-2):101-8. PubMed ID: 15345309
[TBL] [Abstract][Full Text] [Related]
3. 3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo.
Wu W; Chen Y; d'Avignon A; Hazen SL
Biochemistry; 1999 Mar; 38(12):3538-48. PubMed ID: 10090740
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilic granuloma of the bone in Hand-Schüller-Christian disease: extensive in vivo eosinophil degranulation and subsequent binding of released eosinophil peroxidase (EPO) to other inflammatory cells.
Zabucchi G; Soranzo MR; Menegazzi R; Cattin L; Vecchio M; Lanza F; Patriarca P
J Pathol; 1991 Mar; 163(3):225-31. PubMed ID: 1707451
[TBL] [Abstract][Full Text] [Related]
5. [The role of eosinophil in nasal allergy].
Yoshimi R
Nihon Rinsho; 1993 Mar; 51(3):820-4. PubMed ID: 8492464
[TBL] [Abstract][Full Text] [Related]
6. A kinetic assay for eosinophil peroxidase activity in eosinophils and eosinophil conditioned media.
White SR; Kulp GV; Spaethe SM; Van Alstyne E; Leff AR
J Immunol Methods; 1991 Nov; 144(2):257-63. PubMed ID: 1660059
[TBL] [Abstract][Full Text] [Related]
7. Antigen-mediated pulmonary eosinophilia in immunoglobulin G1-sensitized guinea pigs: eosinophil peroxidase as a simple specific marker for detecting eosinophils in bronchoalveolar lavage fluid.
Cheng JB; Pillar JS; Shirley JT; Showell HJ; Watson JW; Cohan VL
J Pharmacol Exp Ther; 1993 Feb; 264(2):922-9. PubMed ID: 8437132
[TBL] [Abstract][Full Text] [Related]
8. Extracellular release of rat eosinophil peroxidase (EPO) I. Role of anaphylactic immunoglobulins.
Khalife J; Capron M; Grzych JM; Bazin H; Capron A
J Immunol; 1985 Mar; 134(3):1968-74. PubMed ID: 3968436
[TBL] [Abstract][Full Text] [Related]
9. Studies of cellular mechanisms for the generation of superoxide by guinea-pig eosinophils and its dissociation from granule peroxidase release.
Shute JK; Rimmer SJ; Akerman CL; Church MK; Holgate ST
Biochem Pharmacol; 1990 Nov; 40(9):2013-21. PubMed ID: 2173598
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of degranulation from human eosinophils by platelet-activating factor.
Kroegel C; Yukawa T; Dent G; Venge P; Chung KF; Barnes PJ
J Immunol; 1989 May; 142(10):3518-26. PubMed ID: 2541198
[TBL] [Abstract][Full Text] [Related]
11. Human eosinophil peroxidase: purification and characterization.
Carlson MG; Peterson CG; Venge P
J Immunol; 1985 Mar; 134(3):1875-9. PubMed ID: 3918110
[TBL] [Abstract][Full Text] [Related]
12. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion.
Carlson M; Raab Y; Peterson C; Hällgren R; Venge P
Am J Gastroenterol; 1999 Jul; 94(7):1876-83. PubMed ID: 10406252
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte function in the airways of allergen-challenged pigs: effects of inhaled and systemic budesonide.
Fornhem C; Peterson CG; Dahlbäck M; Scheynius A; Alving K
Clin Exp Allergy; 1996 Dec; 26(12):1436-48. PubMed ID: 9027445
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effect of AS-35. a novel antiallergic drug, on chemical mediator release from human eosinophils].
Kawashima T; Nagaki S; Iwakaji A; Iwamoto I; Yoshida S; Tomioka H
Arerugi; 1994 Dec; 43(11):1326-30. PubMed ID: 7887808
[TBL] [Abstract][Full Text] [Related]
15. Partial purification and biological properties of an eosinophil-activating factor.
Thorne KJ; Richardson BA; Veith MC; Tai PC; Spry CJ; Butterworth AE
Eur J Immunol; 1985 Nov; 15(11):1083-91. PubMed ID: 2998804
[TBL] [Abstract][Full Text] [Related]
16. Mutual influence between eosinophil peroxidase (EPO) and neutrophils: neutrophils reversibly inhibit EPO enzymatic activity and EPO increases neutrophil adhesiveness.
Zabucchi G; Menegazzi R; Cramer R; Nardon E; Patriarca P
Immunology; 1990 Apr; 69(4):580-7. PubMed ID: 2335377
[TBL] [Abstract][Full Text] [Related]
17. Platelet-activating factor induces eosinophil peroxidase release from purified human eosinophils.
Kroegel C; Yukawa T; Dent G; Chanez P; Chung KF; Barnes PJ
Immunology; 1988 Jul; 64(3):559-61. PubMed ID: 3410498
[TBL] [Abstract][Full Text] [Related]
18. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils.
Kita H; Abu-Ghazaleh RI; Sur S; Gleich GJ
J Immunol; 1995 May; 154(9):4749-58. PubMed ID: 7722326
[TBL] [Abstract][Full Text] [Related]
19. FMLP is a potent activator of guinea-pig eosinophils but its activity is dependent on the prior overnight in vitro culture of the cells (facilitation).
Bach MK; Brashler JR
Immunology; 1992 Apr; 75(4):680-7. PubMed ID: 1317350
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition of eosinophil peroxidase release by chymotrypsin type protease inhibitors from activated human eosinophils].
Kawaji K; Matsunaga Y; Kido H; Ogura T
Arerugi; 1993 Oct; 42(10):1591-9. PubMed ID: 8250722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
